{
    "clinical_study": {
        "@rank": "16654", 
        "arm_group": [
            {
                "arm_group_label": "LY2409021 Mild Renal Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive a single 80 mg dose of LY2409021 orally on Day 1 of the study"
            }, 
            {
                "arm_group_label": "LY2409021 Moderate Renal Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive a single 80 mg dose of LY2409021 orally on Day 1 of the study"
            }, 
            {
                "arm_group_label": "LY2409021 Severe Renal Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive a single 80 mg dose of LY2409021 orally on Day 1 of the study"
            }, 
            {
                "arm_group_label": "LY2409021 End Stage Renal Disease", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive a single 80 mg dose of LY2409021 orally on Day 1 of Period 1 of the study and a single 80 mg dose of LY2409021 orally on Day 1 of Period 2 of the study"
            }, 
            {
                "arm_group_label": "LY2409021 Control", 
                "arm_group_type": "Experimental", 
                "description": "Healthy participants will receive a single 80 mg dose of LY2409021 orally on Day 1 of the study"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to measure how much of the study drug, LY2409021, gets into the\n      blood stream and how long it takes the body to get rid of it when given to participants with\n      different levels of kidney function. There are five study groups.    Each participant may\n      only enroll in one group. Participants in groups 1 through 4 may be healthy or may have\n      mild, moderate, or severe kidney disease.  They will complete one study period lasting about\n      29 days. Study group 5 will enroll participants with kidney disease who are on dialysis.\n      They will complete two study periods which together last about 59 days. Screening is\n      required within 21 days prior to the start of the study for all participants."
        }, 
        "brief_title": "A Study of LY2409021 in Participants With Different Levels of Kidney Function", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Kidney Failure, Chronic", 
            "Renal Insufficiency, Chronic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Failure, Chronic", 
                "Renal Insufficiency", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Inclusion Criteria for ALL Participants\n\n          -  Male participants must agree to use a reliable method of birth control in addition to\n             having their partner use another method for the duration of the study and for 3\n             months after the last dose of LY2409021\n\n          -  Female participants must not be of child-bearing potential\n\n          -  Participants have a body mass index (BMI) of 18 to 40 kilogram per meter square\n             (kg/m^2), inclusive, at screening\n\n        Additional Inclusion Criteria for Control (Healthy) Participants\n\n        - Control participants must have normal renal function, assessed by mean estimated\n        creatinine clearance (CLcr) greater than or equal to (\u2265)90 milliliter per minute (mL/min)\n        at screening and day before dosing\n\n        Additional Inclusion Criteria for Participants with Mild-to-Severe Renal Impairment or End\n        Stage Renal Disease (ESRD)\n\n        - Males or females with stable mild-to-severe renal impairment, assessed by estimated\n        CLcr, or with ESRD requiring hemodialysis (or hemodiafiltration) for at least 3 months\n\n        Additional Inclusion Criteria for Participants with Type 2 Diabetes Mellitus (T2DM)\n\n        - Participants with T2DM that are being treated with diet or exercise alone or receive\n        treatment with insulin\n\n        Exclusion Criteria:\n\n        Exclusion Criteria for ALL Participants\n\n          -  Participants that require peritoneal dialysis\n\n          -  Participants that have a current, functioning, organ transplant\n\n          -  Participants who show evidence of significant active uncontrolled endocrine or\n             autoimmune abnormalities (for example, thyroid disease, pernicious anemia) as judged\n             by the screening physician\n\n          -  Participants who had a febrile illness within 3 days prior to screening\n\n          -  Participants with an abnormality in the 12-lead Electrocardiogram (ECG) that, in the\n             opinion of the investigator, increases the risks associated with participating in the\n             study. [Participants with a QT interval corrected using Fridericia's (QTcF) formula\n             >450 millisecond (msec) or a PR interval >0.22 sec on the screening ECG, or who have\n             risk factors for Torsades de Pointes]\n\n          -  Participants who show evidence of significant active neuropsychiatric disease\n\n          -  Participants that are currently using or intend to use potent inhibitors of\n             cytochrome P450 (CYP)3A, which include but are not limited to atazanavir, indinavir,\n             nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone,\n             saquinavir, and telithromycin\n\n          -  Participants who are currently using drugs with a narrow therapeutic index (for\n             example, digoxin,lithium, phenytoin, theophylline, and warfarin)\n\n          -  Participants that are currently using drugs that are known to prolong the QT interval\n\n        Additional Exclusion Criteria for Participants with Mild, Moderate or Severe Renal\n        Impairment or ESRD:\n\n          -  Participants that have used any drug indicated for medical care of the participant's\n             renal impairment, which is not established in dose and administered for at least 7\n             days before LY2409021 administration\n\n          -  Participants with poorly controlled hypertension (systolic blood pressure (BP) less\n             than (>)160, diastolic BP >95 mm Hg) and/or evidence of labile blood pressure\n             including symptomatic postural hypotension\n\n          -  Participants with hemoglobin <9 grams per deciliter (g/dL) or significant active\n             hematologic disease from causes other than underlying renal disease\n\n        Additional Exclusion Criteria for Participants with T2DM:\n\n          -  Participants who use an oral or injectable antihyperglycemic agent, except for\n             insulin, within 1 month prior to dosing (Day 1)\n\n          -  Participants who have experienced a ketoacidotic episode (pH <7.3) requiring\n             hospitalization in the last 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929109", 
            "org_study_id": "14578", 
            "secondary_id": "I1R-MC-GLBT"
        }, 
        "intervention": {
            "arm_group_label": [
                "LY2409021 Mild Renal Impairment", 
                "LY2409021 Moderate Renal Impairment", 
                "LY2409021 Severe Renal Impairment", 
                "LY2409021 End Stage Renal Disease", 
                "LY2409021 Control"
            ], 
            "description": "Administered orally", 
            "intervention_name": "LY2409021", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "81241"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Liverpool", 
                        "country": "United Kingdom", 
                        "state": "Merseyside", 
                        "zip": "L7 8XP"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "Pharmacokinetics of LY2409021 Following Administration to Subjects With Varying Degrees of Renal Function", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of LY2409021", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 336 hours post dose in each period"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2409021", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 336 hours post dose in each period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929109"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of LY2409021 in Participants with ESRD Before and After Dialysis", 
                "safety_issue": "No", 
                "time_frame": "Group 5: Predose up to 336 hours post dose in each period"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2409021 In Participants with ESRD Before and After Dialysis", 
                "safety_issue": "No", 
                "time_frame": "Group 5: Predose up to 336 hours post dose in each period"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}